Keymed Biosciences, Inc. (HK:2162) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Keymed Biosciences Inc. has announced that China’s National Medical Products Administration approved its drug Stapokibart for treating chronic rhinosinusitis with nasal polyposis. The phase III clinical trial showed significant improvements in nasal polyp size and congestion, with a favorable safety profile. This approval marks a significant step for Keymed, showcasing its potential in the pharmaceutical market.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.